Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+972-4-9028100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees184
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions
What is Protalix Biotherapeutics' stock symbol?
Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX."
How were Protalix Biotherapeutics' earnings last quarter?
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) posted its quarterly earnings data on Monday, May, 6th. The company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.02. The business earned $10.44 million during the quarter, compared to the consensus estimate of $10.15 million. During the same period last year, the firm earned ($0.06) earnings per share. View Protalix Biotherapeutics' Earnings History.
When is Protalix Biotherapeutics' next earnings date?
What price target have analysts set for PLX?
1 Wall Street analysts have issued 12-month price objectives for Protalix Biotherapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they expect Protalix Biotherapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 608.4% from the stock's current price. View Analyst Price Targets for Protalix Biotherapeutics.
What is the consensus analysts' recommendation for Protalix Biotherapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protalix Biotherapeutics.
What are Wall Street analysts saying about Protalix Biotherapeutics stock?
Here are some recent quotes from research analysts about Protalix Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. " (6/13/2019)
- 2. HC Wainwright analysts commented, "We note that this would potentially involve Priority Review— i.e., a six-month review period vs. the roughly one-year time frame for standard review applications—for the pegunigalsidase alfa BLA. Over the last several months, Protalix and Chiesi have engaged the FDA in dialog on the eligibility of pegunigalsidase alfa for accelerated approval based on readily-available data generated by Protalix from its clinical studies of pegunigalsidase alfa. As a result of this dialog and based on the content of a recent letter received from the Chiesi have initiated preparations for a BLA submission based on data from the completed Phase 1/2 clinical trials of pegunigalsidase alfa and from the ongoing Phase 3 BRIDGE clinical trial. We consider this update a very positive development for Protalix and thus reiterate our Buy rating and 12-month target price of $3.00 per share." (6/10/2019)
Has Protalix Biotherapeutics been receiving favorable news coverage?
Headlines about PLX stock have been trending somewhat positive on Sunday, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Protalix Biotherapeutics earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Protalix Biotherapeutics.
Are investors shorting Protalix Biotherapeutics?
Protalix Biotherapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totalling 2,749,205 shares, a drop of 2.6% from the April 15th total of 2,822,725 shares. Based on an average daily volume of 193,928 shares, the days-to-cover ratio is currently 14.2 days. Currently, 2.0% of the company's shares are sold short. View Protalix Biotherapeutics' Current Options Chain.
Who are some of Protalix Biotherapeutics' key competitors?
Some companies that are related to Protalix Biotherapeutics include Emblem (EMC), 22nd Century Group (XXII), IMV (IMV), Pfenex (PFNX), Horizon Discovery Group (HZD), Enochian Biosciences (ENOB), CEL-SCI (CVM), Bioventix (BVXP), OncoCyte (OCX), OncoCyte (OCX), MediGene (MDG1), Arix Bioscience (ARIX), IMV (IMV), CorMedix (CRMD) and BioTime (BTX).
What other stocks do shareholders of Protalix Biotherapeutics own?
Who are Protalix Biotherapeutics' key executives?
Protalix Biotherapeutics' management team includes the folowing people:
- Mr. Moshe Manor, CEO, Pres & Director (Age 63)
- Dr. Yoseph Shaaltiel, Founder and Exec. VP R&D (Age 65)
- Mr. Yossi Maimon CPA, CPA, MBA, CFO, VP, Treasurer & Sec. (Age 48)
- Mr. Yaron Naos, Sr. VP of Operations (Age 55)
- Dr. Einat Brill-Almon, Sr. VP of Product Devel. (Age 59)
How do I buy shares of Protalix Biotherapeutics?
Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protalix Biotherapeutics' stock price today?
One share of PLX stock can currently be purchased for approximately $0.4235.
How big of a company is Protalix Biotherapeutics?
What is Protalix Biotherapeutics' official website?
How can I contact Protalix Biotherapeutics?
Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100.
MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days.
